Abstract
Contemporary medicine is shifting towards person rather than
disease-oriented care.1With increasing life expectancy and the ageing
of baby boomers, the proportion over 60 years is growing faster
than the overall population, with worldwide estimates reaching
2 billion by 2050 (http://www.un.org/esa/population/publications/
worldageing19502050).2 In parallel, acute coronary syndromes
(ACS) and atrial fibrillation (AF)—the most frequent indications
for dual platelet inhibition or anticoagulation—occur mostly in older
patients.2 – 6 There is general agreement that people ≥75 years
can be defined ‘elderly’; however, cutoffs as low as 65 years have
been applied to important clinical datasets and risk scores.3,7 – 10
Lingua originale | English |
---|---|
pagine (da-a) | 3238-3249 |
Numero di pagine | 12 |
Rivista | European Heart Journal |
Volume | 36 |
DOI | |
Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- antithrombotic therapy
- elderly